

# Major Depressive Disorder (MDD) in Children under Age 6

### Level 0

Comprehensive assessment. Refer to *Principles of Practice* on page 5.



### Level 1

Psychotherapeutic intervention (e.g., dyadic therapy) for 6 to 9 months; assessment of parent/guardian depression and referral for treatment if present.



### Level 2

If poor response to psychosocial treatment after 6 to 9 months, re-assess diagnosis, primary care giver response to treatment, and/or consider switching to a different or more intensive psychosocial treatment. Consider child psychiatric consultation or second opinion.

Under 3 years, refer to *Principles of Practice* on page 5.



### Level 3

If depression is severe, or there is continued poor response to psychosocial treatment alone, consider combination treatment with fluoxetine and concurrent psychosocial treatment.

- ◆ Fluoxetine — 4 to 5 years old
  - ◇ Maximum dose: 5 mg/day
  - ◇ Discontinuation trial after 6 months of any effective medication treatment with gradual downward taper.
  - ◇ **Monitor for behavioral disinhibition and suicidality.** Behavioral disinhibition is defined as impulsive, sensation seeking behaviors and lack of self-regulation.

### Not Recommended:

- ◆ The use of medication without psychosocial treatment.
- ◆ Use of tricyclic antidepressants (TCAs) or paroxetine.

*Note: In preschool children, MDD is very rare (point prevalence is thought to be 0.5%).*

# Major Depressive Disorder (MDD) in Children and Adolescents Ages 6 to 17 Years Old

## Level 0

### Assessment

- ◆ Screening using multi-informant, validated rating scales that include depression and screening for comorbidity (other psychiatric and medical conditions):
  - ◇ Center for Epidemiological Studies Depression Scale for Children Patient Health Questionnaire (CES-DC)
  - ◇ Patient Health Questionnaire-9 (PHQ-9)
  - ◇ Pediatric Symptom Checklist (PSC)

*Note: The above scales are available at <http://medicaidmentalhealth.org/>.*
- ◆ Perform risk assessment: Specific screen for harm to self or others and access to firearms, knives/sharps, and other lethal means such as alcohol, prescription and non-prescription medications.
- ◆ Evaluate sleep hygiene, diet, and exercise.
- ◆ Address environmental stressors such as abuse, bullying, conflict, functioning at school, peer relationships, family dysfunction, and caregiver depression.
- ◆ **Establish a safety plan:**
  - ◇ Removal of firearms, knives/sharps, and other lethal means such as alcohol, prescription and non-prescription medications.
  - ◇ **Develop an emergency action plan:**
    - Provide adolescents with mutually agreeable and available emergency numbers and contacts.
    - Engage a concerned third party familiar with the adolescent.
- ◆ Positive screen: DSM-5 based interview evaluation.
- ◆ Consider medical reason for depression [e.g., hypothyroidism, B12/folate deficiency, anemia, malnutrition (with or without eating disorder), chronic disorder (diabetes, asthma, inflammatory bowel disease, juvenile rheumatoid disease, infectious mononucleosis, etc.)].
- ◆ Rule out iatrogenic etiology of depression (i.e., medication side effects/interactions).
- ◆ Evaluate past psychiatric and medical history, previous treatment, family conflict and current depression of family and caregivers, bullying, abuse, peer conflict, school issues, and substance abuse.
- ◆ Consider and rule out presence of bipolar depression. Pointers: Prior (hypo) mania, family history of bipolar disorder, atypical depression with reverse neurovegetative signs, seasonal affective component, brief and recurrent episodes, and melancholic depression in prepubertal child.

# Major Depressive Disorder (MDD) in Children and Adolescents Ages 6 to 17 Years Old (continued)

## Level 0 (continued)

- ◆ Track outcomes using empirically validated tools. Refer to DSM-5 Severity Measure for Depression, Child Age 11–17 available and Child Depression Inventory (CDI) available at <http://www.medicaidmentalhealth.org/>.

*Note: The Child Depression Inventory is not available in the public domain.*

Always monitor for:

- ◆ Emergence or exacerbation of suicidality and balance the risk–benefit profile of antidepressants during the acute treatment phase.
- ◆ Behavioral activation (e.g., difficulty falling asleep, increased motor activity, increased talkativeness)
- ◆ Adverse events
- ◆ Treatment adherence
- ◆ Treatment or inherently emergent comorbidity
- ◆ Potential development of (hypo)mania



## Level 1

Initial treatment plan

- ◆ Active support: 6 week trial (if mild symptoms).
  - ◇ Components of active support must include psychosocial interventions and psychoeducation and may include: Self-help materials, active listening/relationship building, school involvement, mood monitoring, pleasant activities, cognitive restructuring, family conflict reduction, sleep hygiene, and exercise.

## Major Depressive Disorder (MDD) in Children and Adolescents Ages 6 to 17 Years Old *(continued)*

	<p><b>Level 2</b></p> <p>Reassess diagnosis first (e.g., bipolar disorder), rule out psychostimulant or substance abuse related psychosis. Targeted treatments if symptoms are moderate to severe, impairment continues, and/or no response to active support. Start with Cognitive Behavioral Therapy (CBT), Interpersonal Therapy (IPT), depression-specific behavioral family therapy.</p> <ul style="list-style-type: none"> <li>◆ <b>2a.</b> Fluoxetine or combination of CBT or IPT psychotherapy with fluoxetine.</li> <li>◆ <b>2b.</b> May consider use of escitalopram for age 12 and above.</li> </ul> <p><b>Qualifiers:</b></p> <ul style="list-style-type: none"> <li>◆ Mild: Psychosocial interventions only.</li> <li>◆ Moderate/Severe: Combination of CBT or IPT psychotherapy with fluoxetine.</li> <li>◆ Psychosis: SSRIs (fluoxetine, escitalopram) plus consider antipsychotics (adult data only). Careful evaluation of symptoms to determine the degree of psychosis to warrant the use of antipsychotics.</li> <li>◆ Comorbidity: Combination of CBT or IPT psychotherapy with fluoxetine; treat comorbidity.</li> <li>◆ Suicidality: Intensify surveillance and follow-up; combination therapy with CBT or IPT psychotherapy if on antidepressant only or remove antidepressant if otherwise ineffective; if chronic, consider lithium augmentation.</li> </ul>
	<p><b>Level 3</b></p> <p>Inadequate response</p> <ul style="list-style-type: none"> <li>◆ If no clinical response to the medication utilized in Level 2, switch to another medication listed above.</li> </ul>
	<p><b>Level 4</b></p> <p>Poor or non-response</p> <ul style="list-style-type: none"> <li>◆ Refer to mental health specialist.</li> <li>◆ Re-assess diagnosis (bipolar disorder, substance use disorder, anxiety disorders, PTSD), rule out medical condition (e.g., hypothyroidism), or medication side effects.</li> <li>◆ Increase psychosocial intervention and medication dose if tolerated.</li> <li>◆ Augment with alternate psychosocial intervention (either CBT or IPT).</li> <li>◆ Consider change in level of care (treatment setting and interventions based on severity of illness).</li> <li>◆ For milder form and/or seasonal affective symptoms with light sensitivity, consider bright light therapy.</li> </ul>

## Major Depressive Disorder (MDD) in Children and Adolescents Ages 6 to 17 Years Old (continued)

	<p><b>Level 5</b></p> <p>If poor or non-response to Level 4 interventions</p> <ul style="list-style-type: none"><li>◆ Switch previously used SSRIs to sertraline, citalopram, bupropion or venlafaxine, especially in those who do not have access to psychotherapy or have not responded to non-pharmacological interventions.</li><li>◆ Consider augmentation of SSRI with bupropion, thyroxine, lithium, buspirone, mirtazapine, aripiprazole, quetiapine, or risperidone (adult data only).</li><li>◆ If psychotic/severe: ECT (for adolescents).</li></ul> <p><b>Notes:</b></p> <ul style="list-style-type: none"><li>◆ Factors favoring maintenance treatment (at any Level):<ul style="list-style-type: none"><li>◇ Partial response</li><li>◇ Prior relapse</li><li>◇ Suicidality</li><li>◇ Comorbidity risk for relapse</li><li>◇ Environmental risk for relapse</li><li>◇ Family history of relapsing/recurrent major depression</li><li>◇ Lack of return to full premorbid functioning</li></ul></li><li>◆ Maintenance treatment: 9 to 12 months.</li><li>◆ After maintenance treatment: If stable, at level of premorbid functioning, and no anticipated increase in stressors, consider discontinuation trial over 3 to 4 months.</li><li>◆ Venlafaxine: Caution due to robust evidence of a significantly increased risk for suicidal behavior or ideation</li></ul> <p><i>Note on pharmacogenomic testing: The current evidence does not support pharmacogenomic testing in routine psychiatric clinical practice.</i></p>
---	---

For a full list of references, visit <http://medicaidmentalhealth.org/>.

# Major Depressive Disorders (MDD) Resources

## SELECTED RESOURCES

### ■ Guides for Parents:

- ◆ If Your Adolescent Has Depression or Bipolar Disorder: An Essential Resource for Parents (Evans, 2005)
- ◆ Adolescent Depression: A Guide for Parents (Mondimore and Kelly, 2015)
- ◆ Depression and Your Child: A Guide for Parents and Caregivers (Serani, 2013)

### ■ Workbooks for Youth:

- ◆ Think Good, Feel Good: A Cognitive Behavior Therapy Workbook for Young People (Stallard, 2002)
- ◆ How to Get Unstuck from the Negative Much: A Kid's Guide to Getting Rid of Negative Thinking (Sullivan, 2013)

### ■ Books for Children:

- ◆ What to Do When You Grumble Too Much: A Kid's Guide to Overcoming Negativity (Huebner, 2007)
- ◆ The Princess and the Frog: A Story for Children with Depression (Jones, 2015)

### ■ Relevant Websites:

- ◆ American Academy of Child and Adolescent Psychiatry (AACAP) Depression Resource Center: [https://www.aacap.org/aacap/Families\\_and\\_Youth/Resource\\_Centers/Depression\\_Resource\\_Center/Home.aspx](https://www.aacap.org/aacap/Families_and_Youth/Resource_Centers/Depression_Resource_Center/Home.aspx)
- ◆ National Institute of Mental Health—Depression in Children and Adolescents: The National Institute of Mental Health Site on Depression in Children and Adolescents <http://www.nimh.nih.gov/health/topics/depression/depression-in-children-and-adolescents.shtml>
- ◆ National Alliance of the Mentally Ill (NAMI): National Alliance of the Mentally Ill (NAMI) <https://www.nami.org/>
- ◆ Depression and Bipolar Support Alliance: Depression and Bipolar Support Alliance <http://www.dbsalliance.org/site/PageServer?pagename=home>
- ◆ Teen Mental Health Website: <http://teenmentalhealth.org/care/parents/>

*Note: Above resources and website links were updated at the time of publication.*

For a full list of references, visit <http://medicaidmentalhealth.org/>.